79 related articles for article (PubMed ID: 17405359)
1. Successive therapies may extend survival in AIPC. Interview by Alice Goodman.
Petrylak D
RN; 2007 Mar; 70(3):1-2. PubMed ID: 17405359
[No Abstract] [Full Text] [Related]
2. Sipuleucel-T immunotherapy for castration-resistant prostate cancer.
Tanimoto T; Hori A; Kami M
N Engl J Med; 2010 Nov; 363(20):1966; author reply 1967-8. PubMed ID: 21067392
[No Abstract] [Full Text] [Related]
3. Sipuleucel-T immunotherapy for castration-resistant prostate cancer.
Nabhan C
N Engl J Med; 2010 Nov; 363(20):1966-7; author reply 1968. PubMed ID: 21067391
[No Abstract] [Full Text] [Related]
4. Editorial - immunotherapy for prostate cancer.
Djavan B
Can J Urol; 2011 Aug; 18(4):5763. PubMed ID: 21854706
[No Abstract] [Full Text] [Related]
5. Immunotherapies in clinical trials: do they demand different evaluation tools?
Tuma RS
J Natl Cancer Inst; 2011 May; 103(10):780-1. PubMed ID: 21551417
[No Abstract] [Full Text] [Related]
6. Sipuleucel-T (Provenge): active cellular immunotherapy for advanced prostate cancer.
McKarney I
Issues Emerg Health Technol; 2007 Sep; (101):1-4. PubMed ID: 17763575
[TBL] [Abstract][Full Text] [Related]
7. Novel cancer immunotherapy agents with survival benefit: recent successes and next steps.
Sharma P; Wagner K; Wolchok JD; Allison JP
Nat Rev Cancer; 2011 Oct; 11(11):805-12. PubMed ID: 22020206
[TBL] [Abstract][Full Text] [Related]
8. Re: Fabio Calabrò and Cora N. Sternberg. Current indications for chemotherapy in prostate cancer patients. Eur urol 2007;51:17-26.
Di Lorenzo G; Autorino R
Eur Urol; 2007 Aug; 52(2):613-4. PubMed ID: 17416455
[No Abstract] [Full Text] [Related]
9. Therapy: An immune one-two punch.
Bourzac K
Nature; 2015 Dec; 528(7582):S134-6. PubMed ID: 26672788
[No Abstract] [Full Text] [Related]
10. Castration-refractory prostate cancer: new therapies, new questions.
Appleman LJ
Oncology (Williston Park); 2010 Dec; 24(14):1318-9, 1326. PubMed ID: 21294476
[No Abstract] [Full Text] [Related]
11. How does sipuleucel-T alter our clinical practice?
George D
BJU Int; 2010 Oct; 106(7):945-6. PubMed ID: 20931691
[No Abstract] [Full Text] [Related]
12. New drugs: Sipuleucel-T, cabazitaxel, and collagenase clostridium histolyticum.
Hussar DA; Daniels WL
J Am Pharm Assoc (2003); 2010; 50(6):772-5. PubMed ID: 21071329
[No Abstract] [Full Text] [Related]
13. [Therapeutic guidelines in prostate cancer and role for bisphosphonates in bone metastasis].
Miki T; Okihara K
Nihon Rinsho; 2007 Nov; 65 Suppl 9():632-5. PubMed ID: 18161177
[No Abstract] [Full Text] [Related]
14. Special report: treatments for castration-resistant metastatic prostate cancer.
BlueCross BlueShield Association
Technol Eval Cent Assess Program Exec Summ; 2013 Apr; 27(7):1-4. PubMed ID: 23865104
[No Abstract] [Full Text] [Related]
15. Highlights from the XII European Cancer Conference Copenhagen, Denmark.
Tyagi P; Price N; Reddy K; Klem J
Clin Prostate Cancer; 2003 Dec; 2(3):137-41. PubMed ID: 15040855
[No Abstract] [Full Text] [Related]
16. Immunotherapeutics in development for prostate cancer.
Harzstark AL; Small EJ
Oncologist; 2009 Apr; 14(4):391-8. PubMed ID: 19342474
[TBL] [Abstract][Full Text] [Related]
17. Sipuleucel-T.
Higano CS; Small EJ; Schellhammer P; Yasothan U; Gubernick S; Kirkpatrick P; Kantoff PW
Nat Rev Drug Discov; 2010 Jul; 9(7):513-4. PubMed ID: 20592741
[No Abstract] [Full Text] [Related]
18. Prostate cancer treatment: the times they are a' changin'.
Kirby R; Challacombe B; Dasgupta P; Fitzpatrick JM
BJU Int; 2012 Nov; 110(10):1408-11. PubMed ID: 22937730
[No Abstract] [Full Text] [Related]
19. [Advanced prostatic carcinoma--which hormone therapy when?].
Studer UE
Urologe A; 1995 Sep; 34(5):361-6. PubMed ID: 7483151
[No Abstract] [Full Text] [Related]
20. Management of metastatic castration-resistant prostate cancer after first-line docetaxel.
Harrington JA; Jones RJ
Eur J Cancer; 2011 Sep; 47(14):2133-42. PubMed ID: 21658937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
